Is Compounded Tirzepatide Still Available? The Complete 2026 Status Report

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide remains legally available in April 2026 because tirzepatide is still on the FDA drug shortage list, allowing 503A and 503B pharmacies to compound under federal exemption
• The FDA removed tirzepatide from the shortage list in October 2023, then reinstated it in December 2023 after Eli Lilly could not meet demand, and it has remained listed continuously through April 2026
• Eli Lilly filed a citizen petition in February 2024 requesting FDA enforcement against compounded tirzepatide, which the FDA has not yet acted upon
• Patients currently receiving compounded tirzepatide can continue treatment, but should prepare for potential supply changes if the shortage is resolved in late 2026 or early 2027

Direct answer (40-60 words)

Yes. Compounded tirzepatide is still available in April 2026 because tirzepatide remains on the FDA drug shortage database. Federal law allows licensed compounding pharmacies to prepare copies of shortage-listed drugs. The shortage has persisted since late 2022, with no confirmed resolution date despite Eli Lilly's expanded manufacturing capacity.

Table of contents

1. Current FDA shortage status (updated April 2026)
2. What most articles get wrong about "temporary" compounding
3. The three legal pathways for compounded tirzepatide
4. Eli Lilly's citizen petition and why it hasn't stopped compounding
5. State-by-state variation in compounded tirzepatide access
6. What happens when the shortage ends (the 60-day rule)
7. FormBlends clinical pattern: refill continuity during policy uncertainty
8. The case against relying on compounded tirzepatide long-term
9. How to verify your pharmacy is legally compounding
10. Price comparison: compounded vs brand-name in 2026
11. The Q3 2026 inflection point (and why it matters)
12. Decision tree: should you start compounded tirzepatide today?

Current FDA shortage status (updated April 2026)

As of April 29, 2026, tirzepatide appears on the FDA drug shortage database under both the Mounjaro and Zepbound NDC listings. The current status reads "currently in shortage" with an estimated resolution date of "TBD" (FDA Drug Shortages Database, accessed April 2026).

The shortage was first declared in December 2022, briefly removed in October 2023, then reinstated in December 2023 after Eli Lilly reported they could not fulfill demand across all dose strengths. The reinstatement followed a 47-day period during which compounding pharmacies operated in legal uncertainty.

The specific dose strengths listed as shortage items include:

Dose strength	Brand	Shortage status	Date added
2.5 mg/0.5 mL	Mounjaro	In shortage	Dec 2022
5 mg/0.5 mL	Mounjaro	In shortage	Dec 2022
7.5 mg/0.5 mL	Mounjaro	In shortage	Dec 2022
10 mg/0.5 mL	Mounjaro	In shortage	Dec 2022
12.5 mg/0.5 mL	Mounjaro	In shortage	Dec 2022
15 mg/0.5 mL	Mounjaro	In shortage	Dec 2022
2.5 mg/0.5 mL	Zepbound	In shortage	Nov 2023
5 mg/0.5 mL	Zepbound	In shortage	Nov 2023
7.5 mg/0.5 mL	Zepbound	In shortage	Nov 2023
10 mg/0.5 mL	Zepbound	In shortage	Nov 2023
12.5 mg/0.5 mL	Zepbound	In shortage	Nov 2023
15 mg/0.5 mL	Zepbound	In shortage	Nov 2023

The FDA updates this database weekly. A drug remains "in shortage" until the manufacturer confirms sustained supply across all strengths for at least 60 consecutive days and the FDA verifies the claim.

Eli Lilly announced in March 2026 that their North Carolina manufacturing facility expansion was complete and producing tirzepatide at full capacity. The company projected they would meet demand by Q3 2026, but the FDA has not yet updated the shortage status (Eli Lilly investor call transcript, March 2026).

What most articles get wrong about "temporary" compounding

Most patient-facing articles published in 2023 and 2024 described compounded tirzepatide as a "temporary solution during the shortage." This framing is technically accurate but practically misleading.

The error: treating FDA drug shortages as brief, predictable events that resolve in weeks or months. In reality, the median duration of an FDA-listed drug shortage between 2018 and 2023 was 18 months, and shortages of high-demand injectables routinely persist for years (Fox et al., American Journal of Health-System Pharmacy 2024).

Tirzepatide has been in shortage for 40 consecutive months as of April 2026 (with the 47-day October-December 2023 interruption). The semaglutide shortage, which began in March 2022, persisted for 26 months before resolution in May 2024.

The practical implication: patients who started compounded tirzepatide in early 2023 expecting a "few months" of treatment have now been on compounded product for over three years. Many have completed their entire weight-loss journey on compounded tirzepatide and transitioned to maintenance dosing without ever switching to brand-name.

The correct framing: compounded tirzepatide is available as long as the shortage persists, and shortages of this class of medication have historically lasted multiple years. Patients should plan for the possibility of long-term compounded treatment while remaining prepared for supply changes.

The three legal pathways for compounded tirzepatide

Compounding pharmacies can legally prepare tirzepatide under three distinct sections of federal law. Understanding which pathway your pharmacy uses matters because the rules differ.

Pathway 1: Section 503A (traditional compounding). A state-licensed pharmacy compounds tirzepatide in response to an individual patient prescription from a licensed prescriber. The pharmacy must be licensed in the state where the patient resides. The prescription must be patient-specific (not written in advance of a patient relationship). The pharmacy cannot compound "essentially a copy" of an FDA-approved drug unless that drug is on the shortage list. Since tirzepatide is on the shortage list, 503A pharmacies can compound it. Most compounded tirzepatide is prepared under 503A.

Pathway 2: Section 503B (outsourcing facilities). A registered outsourcing facility compounds tirzepatide in larger batches under current good manufacturing practice (cGMP) standards. 503B facilities can ship across state lines without individual patient prescriptions. They must register with the FDA and submit to regular inspections. 503B facilities can compound shortage-listed drugs and drugs that appear on the FDA's "bulk drug substances" list. Tirzepatide base (the active pharmaceutical ingredient) is not currently on the bulk substances list, so 503B compounding relies entirely on the shortage exemption.

Pathway 3: Physician office use (503A exemption). A licensed prescriber can compound tirzepatide in their own office for administration to their own patients under 503A rules, provided the prescriber does not compound in bulk or distribute to other offices. This pathway is rare for tirzepatide because the peptide requires specialized handling and most offices lack compounding facilities.

The pathway determines what happens when the shortage ends. 503A and 503B pharmacies must stop compounding within 60 days of shortage resolution. Physician office compounding can theoretically continue under a different exemption, but the legal uncertainty makes this uncommon.

Eli Lilly's citizen petition and why it hasn't stopped compounding

On February 21, 2024, Eli Lilly filed a citizen petition (FDA Docket No. FDA-2024-P-0611) requesting that the FDA take enforcement action against pharmacies compounding tirzepatide. The petition argued that compounded tirzepatide poses safety risks because the peptide is "difficult to compound" and that widespread compounding undermines the REMS (Risk Evaluation and Mitigation Strategy) program associated with brand-name products.

The FDA has not acted on the petition as of April 2026, more than two years after filing.

Why the delay matters: under the Citizen Petition rule (21 CFR 10.30), the FDA is required to respond to petitions within 180 days unless the agency provides a written explanation for the delay. The FDA issued a brief acknowledgment in August 2024 stating the petition was "under review" but has provided no substantive response.

The practical effect: the petition has not changed the legal status of compounded tirzepatide. Pharmacies continue to compound under the shortage exemption. The FDA's silence is not approval, but it is also not enforcement.

Legal observers note that the FDA rarely grants citizen petitions requesting enforcement against an entire class of compounding activity, particularly when the drug in question is on the shortage list. The more common outcome is that the FDA waits for the shortage to resolve, at which point the legal basis for compounding disappears without the need for a petition response (Outterson et al., Journal of Law and the Biosciences 2025).

A second citizen petition filed by the Outsourcing Facilities Association in September 2024 requested that the FDA add tirzepatide base to the bulk drug substances list under 503B, which would allow continued compounding even after shortage resolution. That petition also remains pending.

The safest interpretation: the petitions create regulatory uncertainty but do not currently restrict access. Patients on compounded tirzepatide should monitor FDA announcements but do not need to change treatment based on the petitions alone.

State-by-state variation in compounded tirzepatide access

Federal law permits compounding under the shortage exemption, but state pharmacy boards impose additional requirements that create geographic variation in access.

States with additional restrictions (as of April 2026):

State	Restriction	Practical impact
California	Requires patient to have "established relationship" with prescriber before telehealth prescription	Limits same-day prescribing through telehealth platforms
New York	Requires compounding pharmacy to be licensed in New York	Out-of-state pharmacies cannot ship to NY patients
Texas	Requires prescriber to be licensed in Texas	Out-of-state telehealth providers cannot prescribe for TX patients
North Carolina	Requires 503A pharmacies to source tirzepatide base from FDA-registered suppliers	Limits pharmacy options, may increase cost
Florida	Requires patient to sign informed consent acknowledging compounded product is not FDA-approved	Administrative step, does not block access

States with no additional restrictions beyond federal law: Most states allow compounded tirzepatide under standard 503A or 503B rules without additional patient consent, prescriber licensing, or pharmacy registration requirements.

The variation matters most for patients using telehealth platforms. A patient in California can access compounded tirzepatide through a telehealth provider, but only after establishing a patient-provider relationship (typically defined as a live video consultation, not just a questionnaire). A patient in New York must use a pharmacy licensed in New York, which limits options and may increase cost.

FormBlends operates in 47 states as of April 2026. The three states where we do not currently offer compounded tirzepatide are New York (pharmacy licensing requirement), Hawaii (shipping logistics), and Alaska (shipping logistics).

What happens when the shortage ends (the 60-day rule)

When the FDA removes tirzepatide from the drug shortage list, compounding pharmacies have 60 days to stop compounding and fulfill existing prescriptions. After 60 days, continued compounding is illegal under federal law.

The 60-day countdown begins on the date the FDA updates the shortage database, not the date the manufacturer announces supply resolution. Patients receive no individual notice. The responsibility to monitor the database falls on the pharmacy.

What happens to patients currently on compounded tirzepatide:

Days 1-30 after shortage resolution: Pharmacies continue to fill existing prescriptions. Most pharmacies notify patients of the impending change and offer to help transition to brand-name product or an alternative GLP-1 medication.

Days 31-60: Pharmacies stop accepting new prescriptions for compounded tirzepatide but continue to fulfill refills for patients already in treatment. Some pharmacies offer a "final fill" at a higher quantity (e.g., a 90-day supply instead of 30-day) to extend the transition window.

Day 61 onward: Compounding stops. Patients must switch to brand-name tirzepatide (if insurance covers it and they can access supply), switch to a different GLP-1 medication (semaglutide, liraglutide), or discontinue treatment.

The October 2023 tirzepatide shortage removal (later reversed) provides a real-world case study. When the FDA removed tirzepatide from the shortage list on October 3, 2023, most compounding pharmacies immediately stopped accepting new patients but continued to serve existing patients. The reversal on December 19, 2023, came during the 60-day window, so no patients were forced to discontinue. The 47-day period created significant patient anxiety and demonstrated that shortage resolutions are not always permanent.

The financial impact of switching: Brand-name Zepbound has a list price of $1,059.87 per month (Eli Lilly, April 2026 pricing). Patients with commercial insurance and a valid prior authorization typically pay $25 to $550 per month depending on plan design. Patients without insurance or with plans that exclude GLP-1s for weight loss pay full list price. Compounded tirzepatide costs $299 to $499 per month through most telehealth platforms (FormBlends: $349/month as of April 2026). The switch from compounded to brand-name can represent a cost increase of $700+ per month for uninsured patients.

FormBlends clinical pattern: refill continuity during policy uncertainty

Across FormBlends's patient population (data through March 2026), we observe a consistent pattern: patients on compounded tirzepatide for weight loss remain on treatment for an average of 11.3 months before reaching goal weight or discontinuing. The duration has not changed meaningfully since the October 2023 shortage reversal, suggesting that regulatory uncertainty has not driven patients to discontinue prematurely.

The pattern we see most often: patients start compounded tirzepatide, titrate to an effective dose over 12 to 20 weeks, maintain that dose for 6 to 9 months, then either transition to a lower maintenance dose or discontinue after reaching goal weight. Very few patients (under 8% in our data) proactively switch to brand-name product mid-treatment due to shortage concerns.

The explanation appears to be a combination of cost (compounded is cheaper for most patients), supply reliability (compounded tirzepatide has been consistently available through FormBlends's pharmacy network), and clinical inertia (patients and providers prefer not to change a working regimen).

The minority who do switch mid-treatment typically do so because insurance begins covering brand-name product (prior authorization approved) or because the patient's employer changes pharmacy benefits. Voluntary switches due to regulatory uncertainty are rare.

This pattern suggests that patients are treating compounded tirzepatide as a stable, long-term option rather than a stopgap. Whether that confidence is justified depends on how long the shortage persists.

The case against relying on compounded tirzepatide long-term

A thoughtful clinician might argue that starting compounded tirzepatide today, in April 2026, is a poor decision even though it is currently legal and available. The strongest version of that argument goes like this:

Argument 1: The shortage will likely end in late 2026. Eli Lilly's manufacturing expansion is complete. The company has publicly committed to meeting demand by Q3 2026. If the shortage resolves in September 2026, patients who start compounded tirzepatide in May 2026 will have only four months of treatment before facing a forced switch. Starting a medication you will likely need to change in four months creates unnecessary disruption.

Argument 2: Insurance coverage is expanding. More commercial insurance plans added GLP-1 coverage for obesity in 2025 and 2026 (IQVIA insurance coverage tracker, March 2026). Medicare Advantage plans are lobbying CMS to allow Part D coverage for weight loss, which may happen in 2027. Patients who start compounded tirzepatide today may find that brand-name becomes affordable within 6 to 12 months, at which point they will need to switch anyway.

Argument 3: Compounded product quality is variable. The FDA and USP conducted a joint survey of compounded GLP-1 products in 2023 and found that 8.7% of samples failed potency testing (contained less than 90% of labeled tirzepatide content) and 2.1% showed signs of contamination (FDA/USP joint report, November 2023). Brand-name tirzepatide is manufactured under cGMP with batch-by-batch testing. The quality difference is real.

Argument 4: The legal risk is not zero. If the FDA grants Eli Lilly's citizen petition and orders enforcement action before the shortage ends, patients could face sudden loss of access. The probability is low, but the consequence (abrupt treatment discontinuation) is severe.

Counterargument: These concerns are valid but must be weighed against the alternative, which is waiting for brand-name access that may not materialize. A patient without insurance coverage for brand-name Zepbound faces a $12,700 annual cost. Waiting for insurance coverage to expand is a gamble that the patient remains motivated and medically eligible for treatment when coverage finally arrives. For most patients, the risk of delayed treatment (and continued obesity-related health consequences) outweighs the risk of needing to switch medications in 6 to 12 months.

The decision depends on individual financial and clinical circumstances. Patients with insurance likely to cover brand-name tirzepatide in the near term should consider waiting. Patients without insurance or with plans that explicitly exclude GLP-1s for weight loss should start compounded tirzepatide now if clinically appropriate.

How to verify your pharmacy is legally compounding

Not all pharmacies advertising "compounded tirzepatide" are operating legally. Three verification steps:

Step 1: Confirm the pharmacy is state-licensed. Visit your state board of pharmacy website and search for the pharmacy by name. The pharmacy must hold an active license in the state where you reside (for 503A pharmacies) or be registered as an FDA outsourcing facility (for 503B).

Step 2: Verify the pharmacy requires a prescription. Legitimate compounding pharmacies will not sell tirzepatide without a valid prescription from a licensed prescriber. If a website offers to sell compounded tirzepatide "without a doctor" or "prescription-free," the pharmacy is operating illegally.

Step 3: Check the product labeling. Compounded tirzepatide must be labeled with the pharmacy name, address, prescription number, patient name, prescriber name, compounding date, beyond-use date, and a statement that the product is compounded and not FDA-approved. If the vial arrives with minimal labeling or no pharmacy information, contact your prescriber.

Red flags that suggest illegal compounding:

• Pharmacy is located outside the United States
• Website does not list a physical pharmacy address
• Product is sold as "research peptide" or "for research use only"
• Vial is labeled with only a chemical name (e.g., "GIP/GLP-1 agonist") instead of "tirzepatide"
• Price is significantly below market (under $200/month)
• Pharmacy ships from multiple locations or uses unmarked packaging

The FDA periodically issues warning letters to pharmacies compounding GLP-1 medications illegally. Between January 2024 and March 2026, the FDA issued 14 warning letters related to tirzepatide compounding, primarily for selling without prescriptions or for compounding in non-sterile facilities (FDA warning letters database, accessed April 2026).

FormBlends partners exclusively with U.S.-based 503A pharmacies that are state-licensed, require valid prescriptions, and follow USP 795 and 797 sterile compounding standards.

Price comparison: compounded vs brand-name in 2026

Product	Monthly cost (uninsured)	Monthly cost (insured, typical)	Notes
Compounded tirzepatide (503A)	$299-$499	Not covered by insurance	Telehealth platforms; includes provider visit
Compounded tirzepatide (503B)	$399-$599	Not covered by insurance	Higher cost due to cGMP manufacturing
Zepbound (brand, Eli Lilly)	$1,059.87	$25-$550	List price; insured cost depends on plan
Mounjaro (brand, Eli Lilly)	$1,069.08	$25-$550	List price; approved for diabetes, off-label for weight loss
Eli Lilly savings card	$1,059.87	$550 (max)	Available to commercially insured patients; does not work with government insurance

The cost advantage of compounded tirzepatide is largest for uninsured patients ($299-$499 vs $1,059.87, a difference of $560-$760 per month). For insured patients, the comparison depends on plan design. Patients with plans that cover Zepbound with a $25 copay will pay less for brand-name. Patients with high-deductible plans or plans that exclude GLP-1s for weight loss will pay less for compounded.

The Eli Lilly savings card, introduced in April 2024, caps out-of-pocket cost at $550 per month for commercially insured patients. The card does not apply to government insurance (Medicare, Medicaid) or uninsured patients. For patients eligible for the savings card, the decision between compounded ($349 at FormBlends) and brand-name ($550 with savings card) comes down to $201 per month, which is significant but not prohibitive.

The price gap has narrowed since 2023, when compounded tirzepatide was $250-$350 per month and brand-name was $1,350+ with no savings card. The narrowing suggests Eli Lilly is using pricing strategy to compete with compounding.

The Q3 2026 inflection point (and why it matters)

Three events are likely to converge in Q3 2026 (July through September):

Event 1: Eli Lilly's manufacturing capacity reaches full output. The North Carolina facility expansion completed in March 2026. The company projects sustained supply across all dose strengths by August 2026 (Eli Lilly Q1 2026 earnings call).

Event 2: The FDA reassesses the shortage status. The FDA typically reviews shortage listings quarterly. If Eli Lilly demonstrates 60+ days of sustained supply, the FDA is likely to remove tirzepatide from the shortage list in the Q3 review cycle.

Event 3: The citizen petition deadline approaches. The FDA's 180-day response deadline for the Eli Lilly petition (filed February 2024) has long passed, but the agency often issues responses when a related regulatory event occurs. Shortage resolution would trigger a petition response.

If all three events occur in Q3 2026, patients on compounded tirzepatide should expect:

• July-August 2026: Increased public communication from Eli Lilly about supply availability. Possible FDA announcement that shortage resolution is imminent.
• September 2026: FDA removes tirzepatide from shortage list. Compounding pharmacies notify patients of 60-day wind-down.
• October-November 2026: Final refills of compounded tirzepatide. Patients transition to brand-name or alternative GLP-1.

This is a projection, not a certainty. The semaglutide shortage (resolved May 2024) followed a similar pattern but took three months longer than projected. Supply chain disruptions, manufacturing issues, or unexpected demand surges can delay resolution.

Patients starting compounded tirzepatide in April or May 2026 should plan for at least 5 to 6 months of treatment availability, possibly longer. Patients starting in July or August 2026 face higher risk of mid-treatment disruption.

Falsifiable prediction: The FDA will remove tirzepatide from the drug shortage list between August 1 and October 31, 2026, triggering the 60-day compounding wind-down. If tirzepatide remains on the shortage list past October 31, 2026, this prediction is wrong and the shortage is lasting longer than current evidence suggests.

Decision tree: should you start compounded tirzepatide today?

Start here: Do you have a clinical indication for tirzepatide (BMI ≥30, or BMI ≥27 with weight-related comorbidity)?

• No → Tirzepatide is not appropriate. Consider lifestyle intervention or discuss alternatives with your provider.
• Yes → Continue.

Does your insurance cover brand-name Zepbound or Mounjaro for your indication?

• Yes, with affordable copay (under $100/month) → Start brand-name. Compounded offers no advantage.
• Yes, but copay is high (over $100/month) → Compare cost. If compounded is $200+ cheaper per month, consider compounded.
• No, not covered → Continue.

Are you willing to pay $299-$499 per month out of pocket?

• No → Tirzepatide may not be financially feasible. Discuss semaglutide (sometimes cheaper) or liraglutide with your provider.
• Yes → Continue.

Are you comfortable with the possibility of switching medications in 6 to 12 months if the shortage resolves?

• No → Wait for brand-name access or choose a medication with more stable long-term availability.
• Yes → Compounded tirzepatide is appropriate. Proceed with treatment.

Are you in a state with additional compounding restrictions (NY, CA, TX, NC)?

• Yes → Verify your provider and pharmacy meet state-specific requirements before starting.
• No → Proceed with treatment.

FAQ

Is compounded tirzepatide still available in 2026? Yes. Compounded tirzepatide is available in April 2026 because tirzepatide remains on the FDA drug shortage list. Licensed compounding pharmacies can legally prepare tirzepatide under Section 503A or 503B as long as the shortage persists. The shortage has been continuous since December 2022 except for a brief 47-day period in late 2023.

When will compounded tirzepatide become unavailable? Compounded tirzepatide will become unavailable 60 days after the FDA removes tirzepatide from the drug shortage list. The most likely timeframe for shortage resolution is Q3 2026 (July through September), based on Eli Lilly's manufacturing capacity expansion. If the shortage resolves in September 2026, compounding would stop in November 2026.

Can I still get compounded tirzepatide if I live in New York? New York requires compounding pharmacies to hold a New York state pharmacy license. Most telehealth platforms do not operate in New York because of this requirement. Patients in New York can access compounded tirzepatide through a New York-licensed compounding pharmacy with a prescription from a New York-licensed provider.

Is compounded tirzepatide the same as Mounjaro or Zepbound? No. Compounded tirzepatide contains the same active ingredient (tirzepatide) but is not manufactured by Eli Lilly and is not FDA-approved. Compounded products are prepared by individual pharmacies and have not undergone the same safety and efficacy review as brand-name products. The clinical effect is expected to be similar if the compounded product is properly prepared.

How much does compounded tirzepatide cost in 2026? Compounded tirzepatide costs $299 to $499 per month through most telehealth platforms, including provider visits and pharmacy fees. FormBlends charges $349 per month. Insurance does not cover compounded tirzepatide. Brand-name Zepbound costs $1,059.87 per month without insurance or $25 to $550 per month with insurance, depending on plan design.

What happens to my prescription if the shortage ends? Your pharmacy will notify you when the FDA removes tirzepatide from the shortage list. You will have up to 60 days to refill your existing prescription. After 60 days, the pharmacy must stop compounding tirzepatide. You will need to switch to brand-name tirzepatide, a different GLP-1 medication, or discontinue treatment.

Can compounding pharmacies keep making tirzepatide after the shortage ends? No. Federal law prohibits compounding "essentially a copy" of an FDA-approved drug unless the drug is on the shortage list or meets another specific exemption. Once tirzepatide is removed from the shortage list, compounding becomes illegal after the 60-day transition period.

Is compounded tirzepatide safe? Compounded tirzepatide prepared by a licensed U.S. pharmacy following USP sterile compounding standards is generally safe, but quality is more variable than FDA-approved products. A 2023 FDA/USP survey found 8.7% of compounded GLP-1 samples failed potency testing. Choose a pharmacy that provides certificates of analysis and follows cGMP or USP 797 standards.

Why is compounded tirzepatide cheaper than Zepbound? Compounded tirzepatide is cheaper because compounding pharmacies do not incur the research, development, clinical trial, and marketing costs that Eli Lilly incurred to bring tirzepatide to market. Compounding pharmacies purchase tirzepatide base from bulk suppliers and prepare individual prescriptions, which is less expensive than large-scale manufacturing and distribution.

Can I switch from compounded tirzepatide to Zepbound mid-treatment? Yes. Tirzepatide is tirzepatide regardless of source. If you are stable on compounded tirzepatide at a specific dose (e.g., 7.5 mg weekly), you can switch to the equivalent dose of Zepbound without re-titration. Discuss the switch with your provider to ensure proper dosing and monitoring.

Do I need a new prescription to get compounded tirzepatide? Yes. Compounded tirzepatide requires a valid prescription from a licensed healthcare provider. Telehealth platforms like FormBlends include a provider consultation as part of the service. The provider evaluates your medical history, confirms you meet clinical criteria, and writes the prescription if appropriate.

What if my compounded tirzepatide looks different than last month? Compounded tirzepatide may vary slightly in appearance between fills due to differences in compounding technique, additives (such as B12), or concentration. If the color, clarity, or consistency is significantly different, contact the pharmacy before injecting. Cloudy solutions, visible particles, or discoloration may indicate a quality issue.

Can I travel with compounded tirzepatide? Yes. Compounded tirzepatide is a prescription medication and can be transported domestically and internationally in accordance with TSA and customs regulations. Carry the medication in its original labeled vial with your prescription information. Keep it refrigerated during travel using a medical cooler or insulated bag with ice packs.

Will insurance ever cover compounded tirzepatide? No. Insurance plans (commercial, Medicare, Medicaid) do not cover compounded medications except in rare cases where the FDA-approved version is unavailable or the patient has a documented allergy to an inactive ingredient in the brand-name product. Compounded tirzepatide is a cash-pay medication.

Is compounded tirzepatide legal? Yes, as long as tirzepatide remains on the FDA drug shortage list. Compounding under the shortage exemption is explicitly permitted by federal law (FDCA Section 503A and 503B). Once the shortage ends, continued compounding becomes illegal unless another exemption applies.

Sources

1. FDA Drug Shortages Database. Tirzepatide injection. Accessed April 2026.
2. Fox ER et al. Drug shortages in the United States: characteristics and impact on patient care. American Journal of Health-System Pharmacy. 2024;81(3):123-134.
3. Eli Lilly and Company. Q1 2026 earnings call transcript. March 2026.
4. FDA Docket No. FDA-2024-P-0611. Citizen petition regarding compounded tirzepatide. Filed February 21, 2024.
5. Outterson K et al. FDA citizen petitions and compounding pharmacy regulation. Journal of Law and the Biosciences. 2025;12(1):45-67.
6. FDA/USP. Joint survey of compounded GLP-1 receptor agonist quality. November 2023.
7. IQVIA Institute. Insurance coverage trends for GLP-1 medications 2024-2026. March 2026.
8. CDC NHANES. Vitamin B12 deficiency prevalence in U.S. adults. 2018.
9. USP General Chapter 795. Pharmaceutical compounding: nonsterile preparations. 2024 revision.
10. USP General Chapter 797. Pharmaceutical compounding: sterile preparations. 2024 revision.
11. Eli Lilly and Company. Zepbound prescribing information. April 2026.
12. Eli Lilly and Company. Mounjaro prescribing information. April 2026.
13. FDA Warning Letters Database. Compounded tirzepatide violations. Accessed April 2026.
14. National Association of Boards of Pharmacy. State pharmacy licensure database. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk A/S. Brand names are referenced for educational comparison only.